Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry

Annals of the Rheumatic Diseases

Volumn 70, Issue 4, 2011, Pages 616-623

  Salmon Ceron, D ^a   Tubach, F ^a   Lortholary, O ^a   Chosidow, O ^b   Bretagne, S ^c   Nicolas, N ^a   Cuillerier, E ^d   Fautrel, B ^e   Michelet, C ^f   Morel, J ^g   Puechal X ^h   Wendling, D ⁱ   Lemann, M ^a   Ravaud, P ^a   Mariette, Xavier ^j  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITÉ PARIS EST   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d Centre Hospitalier General   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^g UNIV MONTPELLIER   (France)

^h CENTRE HOSPITALIER DU MANS   (France)

ⁱ UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^j UNIVERSITÉ PARIS SACLAY   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; STEROID; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; ASPERGILLOSIS; ATYPICAL MYCOBACTERIOSIS; BACTERIAL INFECTION; CASE CONTROL STUDY; CHICKENPOX; CLINICAL ARTICLE; COLITIS; CONTROLLED STUDY; CROHN DISEASE; CRYPTOCOCCOSIS; CYTOMEGALOVIRUS INFECTION; DISEASE REGISTRY; DISEASE SEVERITY; DRUG EXPOSURE; DRUG INDICATION; DRUG SPECIFICITY; FEMALE; FIBROSIS; FRANCE; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; INFECTION RISK; INTENSIVE CARE UNIT; INVASIVE ASPERGILLOSIS; JUVENILE RHEUMATOID ARTHRITIS; LEISHMANIASIS; LISTERIOSIS; MALE; MESENTERIC FIBROSIS; MYCOBACTERIOSIS; MYCOSIS; NOCARDIOSIS; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PNEUMOCYSTOSIS; POLYARTERITIS NODOSA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; PSORIATIC ARTHRITIS; PYODERMA GANGRENOSUM; RHEUMATOID ARTHRITIS; RISK FACTOR; SALMONELLOSIS; SARCOIDOSIS; SPONDYLOARTHROPATHY; TREATMENT DURATION; ULCERATIVE COLITIS; VIRUS INFECTION;

EID: 79952360597     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.137422     Document Type: Article

References (25)

1. Murdaca G, Colombo BM, Puppo F. Anti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events. Int J Immunopathol Pharmacol 2009;22:557-65.
2. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
3. Mohan AK, CotéTR, Block JA, et al. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 2004;39:295-9. (Pubitemid 39050474)
4. Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009;60:1884-94.
5. US Food and Drug administration. Manufacturers of TNF Blocker Drugs Must Highlight Risk of Fungal Infection, 2008. U.S. F.D.A., Silver Spring, Maryland. http://www.fda.gov/bbs/topics/NEWS/2008/NEWS01879.html (accessed 30 December 2008).
6. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85. (Pubitemid 43736578)
7. Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-76. (Pubitemid 44204996)
8. Kaur N, Mahl TC. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci 2007;52:1481-4. (Pubitemid 46776482)
9. Komano Y, Harigai M, Koike R, et al. Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum 2009;61:305-12.
10. Netea MG, Radstake T, Joosten LA, et al. Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression. Arthritis Rheum 2003;48:1853-7. (Pubitemid 36828680)
11. Peña-Sagredo JL, Hernández MV, Fernandez-Llanio N, et al. Listeria monocytogenes infection in patients with rheumatic diseases on TNF-alpha antagonist therapy: the Spanish Study Group experience. Clin Exp Rheumatol 2008;26:854-9.
12. Slifman NR, Gershon SK, Lee JH, et al. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 2003;48:319-24. (Pubitemid 36277998)
13. Tsiodras S, Samonis G, Boumpas DT, et al. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 2008;83:181-94. (Pubitemid 351303102)
14. Tubach F, Ravaud P, Salmon-Céron D, et al. Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists. Clin Infect Dis 2006;43:e95-100.
15. Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009;58 (RR-4):1-207;quiz CE1-4.
16. Salliot C, Gossec L, Ruyssen-Witrand A, et al. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford) 2007;46:327-34. (Pubitemid 46189796)
17. Schneeweiss S, Korzenik J, Solomon DH, et al. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther 2009;30:253-64.
18. Wallis RS, Ehlers S. Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Semin Arthritis Rheum 2005;34 (5 Suppl1):34-8.
19. Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002;46:2565-70. (Pubitemid 36118917)
20. Bergstrom L, Yocum DE, Ampel NM, et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum 2004;50:1959-66. (Pubitemid 38725108)
21. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009;301:737-44.
22. Chakravarty SD, Zhu G, Tsai MC, et al. Tumor necrosis factor blockade in chronic murine tuberculosis enhances granulomatous inflammation and disorganizes granulomas in the lungs. Infect Immun 2008;76:916-26. (Pubitemid 351428050)
23. Wallis RS. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 2008;8:601-11.
24. Greenberg JD, Reed G, Kremer JM, et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis 2010;69:380-6.
25. Noël V, Lortholary O, Casassus P, et al. Risk factors and prognostic influence of infection in a single cohort of 87 adults with systemic lupus erythematosus. Ann Rheum Dis 2001;60:1141-4. (Pubitemid 33096079)